Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia.
Galimberti S, Devidas M, Lucenti A, Cazzaniga G, Möricke A, Bartram CR, Mann G, Carroll W, Winick N, Borowitz M, Wood B, Basso G, Conter V, Zimmermann M, Suciu S, Biondi A, Schrappe M, Hunger SP, Valsecchi MG.
Galimberti S, et al. Among authors: biondi a.
JNCI Cancer Spectr. 2018 Dec 19;2(4):pky069. doi: 10.1093/jncics/pky069. eCollection 2018 Oct.
JNCI Cancer Spectr. 2018.
PMID: 31360884
Free PMC article.